Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABUSNASDAQ:ALGSNASDAQ:ASMBNASDAQ:DVAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$3.19+0.3%$3.35$2.71▼$4.73$609.06M1.2957,305 shs599,655 shsALGSAligos Therapeutics$7.31-1.1%$6.32$3.76▼$46.80$45.19M2.77210,890 shs51,768 shsASMBAssembly Biosciences$18.30+3.2%$14.69$7.75▼$19.93$135.41M0.6227,538 shs49,285 shsDVAXDynavax Technologies$10.16+1.0%$10.17$9.22▼$14.63$1.21B1.032.16 million shs1.43 million shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma+0.31%-4.49%-5.06%-9.12%+1.92%ALGSAligos Therapeutics-1.08%-4.19%+39.24%+12.81%-26.90%ASMBAssembly Biosciences+3.21%+5.72%+18.83%+96.56%+37.08%DVAXDynavax Technologies+0.99%+3.04%+3.25%-20.93%-8.30%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABUSArbutus Biopharma1.9394 of 5 stars3.50.00.00.01.92.50.6ALGSAligos Therapeutics4.2298 of 5 stars3.53.00.04.82.71.70.0ASMBAssembly Biosciences3.6641 of 5 stars3.33.00.04.71.70.00.0DVAXDynavax Technologies4.4291 of 5 stars3.32.00.04.72.21.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABUSArbutus Biopharma 3.00Buy$5.5072.41% UpsideALGSAligos Therapeutics 3.00Buy$70.00857.59% UpsideASMBAssembly Biosciences 2.67Moderate Buy$33.0080.33% UpsideDVAXDynavax Technologies 2.50Moderate Buy$24.00136.22% UpsideCurrent Analyst Ratings BreakdownLatest ALGS, DVAX, ABUS, and ASMB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2025DVAXDynavax TechnologiesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$33.00 ➝ $31.004/17/2025DVAXDynavax TechnologiesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$12.00 ➝ $10.00(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABUSArbutus Biopharma$6.17M99.02N/AN/A$0.51 per share6.25ALGSAligos Therapeutics$3.94M11.34N/AN/A($7.50) per share-0.97ASMBAssembly Biosciences$28.52M4.90N/AN/A$5.25 per share3.49DVAXDynavax Technologies$277.25M4.40$0.16 per share63.53$4.54 per share2.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABUSArbutus Biopharma-$69.92M-$0.41N/AN/AN/A-1,196.64%-75.51%-55.81%8/7/2025 (Estimated)ALGSAligos Therapeutics-$131.21M-$17.51N/AN/AN/A-1,628.75%14.67%7.19%8/5/2025 (Estimated)ASMBAssembly Biosciences-$40.18M-$6.23N/AN/AN/A-124.15%-131.77%-36.81%8/6/2025 (Estimated)DVAXDynavax Technologies$27.31M-$0.52N/A20.73N/A-20.39%3.59%2.20%8/5/2025 (Estimated)Latest ALGS, DVAX, ABUS, and ASMB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ABUSArbutus Biopharma-$0.09-$0.13-$0.04-$0.13$2.54 million$1.76 million5/8/2025Q1 2025ASMBAssembly Biosciences-$2.01-$1.17+$0.84-$1.17$7.41 million$9.42 million5/6/2025Q1 2025ALGSAligos Therapeutics-$2.80-$2.11+$0.69-$2.11$0.33 million$0.31 million5/6/2025Q1 2025DVAXDynavax Technologies$0.03-$0.11-$0.14-$0.77$70.01 million$68.16 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABUSArbutus BiopharmaN/AN/AN/AN/AN/AALGSAligos TherapeuticsN/AN/AN/AN/AN/AASMBAssembly BiosciencesN/AN/AN/AN/AN/ADVAXDynavax TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABUSArbutus Biopharma0.046.016.01ALGSAligos TherapeuticsN/A7.567.56ASMBAssembly BiosciencesN/A2.052.05DVAXDynavax Technologies0.4911.9310.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABUSArbutus Biopharma43.79%ALGSAligos Therapeutics60.43%ASMBAssembly Biosciences19.92%DVAXDynavax Technologies96.96%Insider OwnershipCompanyInsider OwnershipABUSArbutus Biopharma20.30%ALGSAligos Therapeutics4.80%ASMBAssembly Biosciences5.30%DVAXDynavax Technologies2.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABUSArbutus Biopharma90191.53 million152.65 millionOptionableALGSAligos Therapeutics906.11 million5.82 millionNo DataASMBAssembly Biosciences1007.64 million7.23 millionOptionableDVAXDynavax Technologies350120.08 million116.50 millionOptionableALGS, DVAX, ABUS, and ASMB HeadlinesRecent News About These CompaniesDVAX Dynavax Technologies Corporation - Seeking AlphaJune 28, 2025 | seekingalpha.com93,841 Shares in Dynavax Technologies Corporation (NASDAQ:DVAX) Acquired by Advisor Resource CouncilJune 21, 2025 | marketbeat.comSG Americas Securities LLC Reduces Stock Position in Dynavax Technologies Corporation (NASDAQ:DVAX)June 21, 2025 | marketbeat.comExchange Traded Concepts LLC Cuts Stock Position in Dynavax Technologies Corporation (NASDAQ:DVAX)June 18, 2025 | marketbeat.comChicago Capital LLC Has $69.32 Million Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)June 17, 2025 | marketbeat.comDynavax Technologies Co. (NASDAQ:DVAX) Shares Bought by GAMMA Investing LLCJune 16, 2025 | marketbeat.comDynavax re-elects all board members, despite Deep Capital's push to changeJune 11, 2025 | msn.comDynavax elects all four of its nominees after Deep Track proxy fightJune 11, 2025 | reuters.comDynavax Stockholders Elect All Dynavax Director Nominees at 2025 Annual MeetingJune 11, 2025 | prnewswire.comDeep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final Perspectives on Why Change is Needed in the BoardroomJune 9, 2025 | finance.yahoo.comDeep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final ...June 9, 2025 | gurufocus.comDeep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final ...June 9, 2025 | gurufocus.comDeep Track Capital Pushes for Board Changes at Dynavax Technologies Corp (DVAX) | DVAX stock newsJune 9, 2025 | gurufocus.comDynavax Technologies Corp (DVAX) Urges Stockholders to Support Director Nominees | DVAX stock newsJune 9, 2025 | gurufocus.comDynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual MeetingJune 9, 2025 | prnewswire.comFY2027 Earnings Forecast for DVAX Issued By William BlairJune 6, 2025 | marketbeat.comVaccine maker Dynavax's future hangs in balance amid activist investor showdownJune 5, 2025 | bizjournals.comFY2028 Earnings Estimate for DVAX Issued By William BlairJune 5, 2025 | marketbeat.comGlass Lewis Recommends Shareholders Support Deep Track’s Case for Board Change at Dynavax TechnologiesJune 5, 2025 | finance.yahoo.comGlass Lewis backs two of Deep Track's four nominees in Dynavax fightJune 5, 2025 | msn.comDynavax Comments on Glass Lewis RecommendationJune 4, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALGS, DVAX, ABUS, and ASMB Company DescriptionsArbutus Biopharma NASDAQ:ABUS$3.19 +0.01 (+0.31%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$3.14 -0.04 (-1.41%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.Aligos Therapeutics NASDAQ:ALGS$7.31 -0.08 (-1.08%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$7.56 +0.25 (+3.35%) As of 07/2/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Assembly Biosciences NASDAQ:ASMB$18.30 +0.57 (+3.21%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$18.01 -0.29 (-1.61%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.Dynavax Technologies NASDAQ:DVAX$10.16 +0.10 (+0.99%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$10.16 0.00 (0.00%) As of 07/2/2025 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Jefferies Raises Broadcom Price Target to $315: 19% Upside Ahead Dan Ives’ Bold $5 Trillion Forecast for Microsoft Stock 3 Utility Stocks That Combine Income and Stability 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
